학술논문
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Document Type
Article
Author
Logunov, D.Y.; Dolzhikova, I.V.; Shcheblyakov, D.V.; Tukhvatulin, A.I.; Zubkova, O.V.; Dzharullaeva, A.S.; Kovyrshina, A.V.; Lubenets, N.L.; Grousova, D.M.; Erokhova, A.S.; Botikov, A.G.; Izhaeva, F.M.; Popova, O.; Ozharovskaya, T.A.; Esmagambetov, I.B.; Favorskaya, I.A.; Zrelkin, D.I.; Voronina, D.V.; Shcherbinin, D.N.; Semikhin, A.S.; Simakova, Y.V.; Tokarskaya, E.A.; Egorova, D.A.; Shmarov, M.M.; Nikitenko, N.A.; Gushchin, V.A.; Naroditsky, B.S.; Gintsburg, A.L.; Smolyarchuk, E.A.; Zyryanov, S.K.; Borisevich, S.V.
Source
In: The Lancet . (The Lancet, 20 February 2021, 397(10275):671-681)
Subject
Language
English
ISSN
1474547X
01406736
01406736